RxDoctor Payments Data

Rajesh Dandamudi, MD

Internal Medicine · Bay City, MINPI 1942490941

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 68 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$156
  • Pfizer$145
  • Bayer$132
  • Novartis$99
  • Lilly USA, LLC$77
  • GSK$72
  • plus $560 from 16 others

What the payments were for

  • Food & beverage$1,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,241 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$266,805
Medicare patients
759
Services billed
3,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide436$555,697
EliquisApixaban397$389,887
OzempicSemaglutide105$169,433
TrulicityDulaglutide83$141,689
XareltoRivaroxaban119$122,146
JardianceEmpagliflozin76$99,191
FarxigaDapagliflozin Propanediol89$85,353
JanuviaSitagliptin Phosphate44$50,881
MyrbetriqMirabegron57$44,683
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$37,803
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$36,599
EntrestoSacubitril/Valsartan23$35,209
InvokanaCanagliflozin26$32,103
Mirabegron ErMirabegron37$27,973
Breo ElliptaFluticasone/Vilanterol56$27,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$77$697,386519 claims
PfizerEliquis, Paxlovid$145$403,573430 claims
Novo NordiskOzempic$61$169,433105 claims
Johnson & JohnsonXarelto, Invokana$62$154,249145 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$62$133,089108 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$72$73,314105 claims
Astellas Pharma US IncMyrbetriq$43$44,68357 claims
NovartisEntresto$99$35,20923 claims
Sumitomo Pharma America, Inc.Gemtesa$70$14,38111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Bay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →